teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 3 Projects Releases Packages Wiki Activity Actions 61
teleo-codex/entities/health/calibrate.md
Teleo Agents e5765c1c17 vida: extract claims from 2026-04-13-calibrate-glp1-behavioral-interrupted-access-outcomes 
- Source: inbox/queue/2026-04-13-calibrate-glp1-behavioral-interrupted-access-outcomes.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-04-13 04:19:33 +00:00

1.9 KiB
Raw Blame History

Calibrate

Type: Company
Domain: Health
Status: Active
Business Model: Employer-sponsored GLP-1 + behavioral coaching program
Market Position: Premium-tier weight management program ($200-300+/month depending on employer negotiation)

Overview

Calibrate operates an employer-sponsored weight management program combining GLP-1 prescriptions with behavioral coaching across four pillars: food, sleep, exercise, and emotional health. The program targets commercially insured, higher-income populations through employer plans.

Program Structure

  • GLP-1 prescriptions
  • Coaching on food, sleep, exercise, emotional health (four pillars)
  • Regular check-ins and goal tracking
  • Weekly weight tracking (80% member engagement)
  • Coaching session completion (67% member engagement)

Key Metrics

Sample size: n=17,475 members (Endocrine Society 2025 data)

Primary outcomes (uninterrupted access):

  • 12-month weight loss: 15.7% average
  • 18-month: 17.3%
  • 24-month: 17.9% (continued loss, not plateau)
  • Waist circumference reduction: avg 6 inches at 12 months

Interrupted access outcomes:

  • 12-month weight loss: 13.7% (vs. 17% uninterrupted)
  • 24-month: 14.9% (vs. 20.1% uninterrupted)
  • Delta: ~2.2 percentage points at 12 months; ~5.2 percentage points at 24 months

Timeline

  • 2025-01-01 — Presented interrupted access data at Endocrine Society 2025 showing behavioral coaching creates durability floor: members with treatment interruptions maintained 13.7% weight loss at 12 months vs. standard GLP-1 cessation pattern of ~2/3 weight regain

Notes

  • "Treatment interruptions" criteria not publicly specified
  • Endocrine Society presentation not yet peer-reviewed as standalone paper
  • No control condition (Calibrate members without behavioral coaching) to isolate behavioral program effect
  • Sample entirely employer-sponsored, skewing toward commercially insured, higher-income populations